Every material Form 8-K Retension Pharmaceuticals, Inc. has filed with the SEC since October 22, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Retension Pharmaceuticals, Inc. appointed Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026, according to an 8-K filed October 22, 2026. The filing describes his prior accounting and controllership roles and his offer letter terms, which include a $360,000 base salary and a 25,000-share stock option award.
Appointed by the Board on October 21, 2026, effective November 2, 2026, as principal accounting officer
Annual base salary of $360,000 with a discretionary bonus target of 30% of base salary, prorated for 2026
Sign-on bonus of $20,000, subject to continued employment through March 31, 2027
Stock option to buy 25,000 shares, vesting 25% on the first anniversary of the start date, then monthly over 36 months
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Retension Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →